Early development of Calanus hyperboreus nauplii: Response to a changing ocean

To forecast effects of temperature changes on recruitment and population dynamics of the Arctic copepod Calanus hyperboreus, laboratory experiments investigating temperature and food effects on early development were performed in Disko Bay, western Greenland, in 2009, and ascent rates of C. hyperboreus eggs collected in east Greenland were measured in the laboratory. Ascent rates were highly variable both between and within clutches, ranging from 0.7 to 27.7 m d−1, suggesting variability in the biochemical composition of the egg. Development of eggs were investigated between 0.8°C and 6.6°C, and hatching was fitted to a Belěhrádek temperature function (r2 > 0.99) with mean development time (MDT) of eggs ranging from 2.8 to 5.8 d. MDT of fed and starved nauplii was calculated for nauplii raised at 5°C. Fed nauplii developed through the first five nauplius stages (N1–N5) during 40 d of incubation, whereas development of starved nauplii ceased at N3. Nauplii were able to survive at least 30 d of starvation. Respiration rate was measured for N1 and N3 at 0°C, 5°C, and 10°C, and it increased with development stage and temperature from 0.05 ± 0.01 to 0.29 ± 0.08 nmol O2 nauplii−1 h−1 for N1 at 0°C and N3 at 10°C, respectively. A decrease in carbon and lipid content from egg to N3 indicates that nauplii are using stored lipids to cover their metabolic costs during the nonfeeding stages. Early stages of C. hyperboreus seem more affected by temperature than later stages, a vulnerability that might affect future recruitment

O314 Predicting the short-term risk of diabetes in HIV-infected patients in the D:A:D cohort: the D:A:D study group

n/

Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

Background. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Methods. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of antiretroviral drugs, with 130,000 person-years of exposure. Results. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic parameters. Conclusions. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provid